$452.37 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter

Wall Street brokerages forecast that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report sales of $452.37 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $435.50 million and the highest is $461.60 million. Jazz Pharmaceuticals reported sales of $444.61 million during the same quarter last year, which indicates a positive year over year growth rate of 1.7%. The business is scheduled to report its next earnings report on Tuesday, May 14th.

On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.03 billion for the current year, with estimates ranging from $1.95 billion to $2.11 billion. For the next year, analysts forecast that the company will report sales of $2.30 billion, with estimates ranging from $2.21 billion to $2.41 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Jazz Pharmaceuticals.

Get Jazz Pharmaceuticals alerts:

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $3.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.66 by $0.98. The company had revenue of $476.46 million for the quarter, compared to analyst estimates of $459.48 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.95 earnings per share.

JAZZ has been the subject of a number of recent analyst reports. Oppenheimer set a $180.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, December 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $185.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, February 12th. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, December 23rd. BidaskClub raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 18th. Finally, Wolfe Research initiated coverage on shares of Jazz Pharmaceuticals in a research report on Friday, December 14th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $188.56.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 874 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were sold at an average price of $139.50, for a total value of $121,923.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 3,334 shares of Jazz Pharmaceuticals stock in a transaction on Friday, December 14th. The stock was sold at an average price of $140.21, for a total transaction of $467,460.14. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,002 shares of company stock valued at $2,074,027. 3.90% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Enlightenment Research LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth $37,000. First Hawaiian Bank boosted its holdings in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 95 shares during the period. Legacy Financial Advisors Inc. acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth $56,000. Stratos Wealth Partners LTD. acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $106,000. Finally, Riverhead Capital Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $113,000. 91.97% of the stock is owned by hedge funds and other institutional investors.

Shares of JAZZ traded up $0.48 during mid-day trading on Wednesday, reaching $133.00. 575,783 shares of the stock traded hands, compared to its average volume of 710,468. Jazz Pharmaceuticals has a 12-month low of $113.52 and a 12-month high of $184.00. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $7.99 billion, a P/E ratio of 10.87, a P/E/G ratio of 0.88 and a beta of 1.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Leave a Reply

Your email address will not be published. Required fields are marked *